(Q37884434)

24 August 2017

1 reference

title

Treatment of multiple sclerosis: current concepts and future perspectives (English)

1 reference

24 August 2017

0 references

1

Dorothea Buck

1 reference

24 August 2017

Bernhard Hemmer

2

1 reference

24 August 2017

publication date

3 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

258

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

1747-1762

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-011-6101-2

24 August 2017

exact match

0 references

cites work

Immunopathogenesis and immunotherapy of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Pharmacological treatment of early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

The clinical pharmacokinetics of cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Birth outcomes in women who have taken leflunomide during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Daclizumab in treatment of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Campath-1H treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Melanoma following treatment with alemtuzumab for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

Temporal trends in the incidence of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6101-2

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

12 December 2020

Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

1 reference

12 December 2020

Spotlight on anti-CD20.

1 reference

12 December 2020

The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.

1 reference

12 December 2020

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Anti-glomerular basement membrane disease after alemtuzumab

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

1 reference

12 December 2020

Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials

1 reference

12 December 2020

Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE).

1 reference

12 December 2020

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis

1 reference

12 December 2020

JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency.

1 reference

12 December 2020

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

12 December 2020

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

New chemotherapeutic agent: 2-chlorodeoxyadenosine.

1 reference

12 December 2020

Mitoxantrone for multiple sclerosis

1 reference

12 December 2020

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis

1 reference

12 December 2020

10.1007/S00415-011-6101-2

Identifiers

DOI

1 reference

24 August 2017

1 reference